Preclinical development of OR-449, a novel targeted therapy for adrenocortical cancer

$6.93M USD

Funder	NATIONAL CANCER INSTITUTE
Recipient Organization	Orphagen Pharmaceuticals
Country	United States
Start Date	Jul 05, 2021
End Date	Jun 30, 2023
Duration	725 days
Number of Grantees	1
Roles	Principal Investigator
Data Source	NIH (US)
Grant ID	`10445073`

Grant Description

ABSTRACT Adrenocortical carcinoma (ACC) is a rare, aggressive cancer. The majority of cases are metastatic or locally advanced at diagnosis with a dismal five-year survival of